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cost from the employment situation of the parents of 
the child patients from the chart and the interview. Loss
proﬁts were taken into consideration about death cases
or the critical sequelae. RESULTS: Medical expenditure
in outpatient cases was about 120,000 yen on average,
while it was 300,000 yen for hospitalization cases. The
opportunity cost was far exceeded medical expenses.
Beneﬁt Cost ratio (BCR) was 2.5, when the base case was
set up and was presumed. In the result of sensitive analy-
sis of BCR, it ranged from 2.3 at a minimum to about 5
at the maximum. Discussion in the preceding research on
the BCR analysis of vaccination, it is well-known that
BCR is 1.4 for hepatitis B vaccine for infants, 1.93 for
inﬂuenza vaccine for pre-school children, and 1.81 for
inﬂuenza vaccine for healthy adults. When compared
with this research, the result of this research shows the
validity of a measles vaccine strongly. CONCLUSION:
We conclude that measles vaccination is excellent method
of prevention from the viewpoint of cost-beneﬁt analysis.
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OBJECTIVES: The aim of the study was to compare the
highly active antiretroviral therapy either with ritonavir
(RTV)/saquinavir (SQV), lopinavir/ritonavir (LPV/RTV),
indinavir (IDV), nelﬁnavir (NFV) or efavirenz (EFV) in
combination with two nucleoside reverse transcriptase
inhibitors therapy. METHODS: The cost-effectiveness
analysis was conducted. Clinical data were derived from
published clinical trials and large observational cohorts.
The analysis was based on the drug costs solely, obtained
from National AIDS Centre in Poland. Three scenarios
were investigated in the research. The ﬁrst one extended
over a time of 48 weeks of the treatment with a studied
NNRTI or PI. A measure of effectiveness was deﬁned as
a virological suppression of serum HIV-RNA <400
copies/mL at the end of the treatment. In the second 
scenario the initial therapy for HIV infection could be
switched twice in patients who failed their PI- or NNRTI-
based treatment regimen. The time horizon of the analy-
sis was set to 144 weeks, i.e. 3 cycles—48 weeks each. A
measure of effectiveness was deﬁned as virological sup-
pression at any point of time during the whole time
horizon. In the third scenario the time horizon lasted for
10 cycles (480 weeks) of HIV-infection treatment, with
two changes of treatment regimens in case of failure. In
this scenario the measure of effectiveness was deﬁned 
as a number of cycles with a serum HIV-RNA <400
copies/ml. RESULTS: LPV/RTV proved to be the most
cost-effective combination in the ﬁrst two scenarios
having the cost-effectiveness ratio (C/E ratio) of 22987
PLN (Polish zlotys) and 23594 PLN, respectively. In the
third scenario EFV was the most cost-effective therapy
with a C/E ratio of 15254 PLN. The sensitivity analysis
turned out in all scenarios the combination LPV/RTV 
had the smallest standard error of C/E ratio proving to
be more attractive. The sensitivity analysis proved the
robustness of the obtained results against the assumptions
taken. CONCLUSIONS: Depending on the scenario pre-
sumed either the therapy containing LPV/RTV or EFV is
the most cost-effective alternative of the treatment of
HIV-infection in Poland.
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OBJECTIVES: To estimate the hospitalisation costs, both
on average and for selected subgroups, for severe infec-
tion with the respiratory syncytial virus (RSV) in young
children. METHODS: We collected data of children hos-
pitalised for severe RSV infection during four seasons
1996/97, 1997/98, 1998/99, and 1999/2000 in 29 hospi-
tals in the Southwest of The Netherlands (n = 3,487). Five
patient characteristics (sex, gestational age, presence of
bronchopulmonary disease (BPD), birth weight and age)
were collected for all patients together with the number
of hospital days. In addition, detailed information of 20
resources related to daily hospital care was collected 
for children hospitalised in the last season (1999/2000).
Volumes of care were obtained from hospital registries
and questionnaires among nurses and physicians. Prices
were based on hospital accounts and national salary
guidelines. For the last season (n = 946), the individual
total hospitalisation costs were directly calculated. We
estimated the costs for the children hospitalised in the ﬁrst
three seasons (1996/97, 1997/98, and 1998/99) based on
the correlation of costs with the number of hospital days
and the 5 patient characteristics using a linear regres-
sion model. RESULTS: The number of hospital days
accounted for >80% of the variety in total hospitalisation
costs in the season 1999/2000. The average total costs of
the season 1999/2000 were €3,135 per child. The costs
for children with low gestational age were considerably
higher (€5,325 for a child with gestational age ‹28
weeks). Also, hospitalisation of a child with BPD was
more expensive (€5,870). CONCLUSIONS: The hospital
related costs of severe RSV infections in young children
were primarily determined by the number of hospital
days. Therefore, we could estimate the hospitalisation
costs for four RSV seasons, although detailed informa-
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tion on hospital care was only collected for one season.
More individualised estimates of hospitalisation costs
may be obtained with patient characteristics such as ges-
tational age and presence of BPD.
PIN22
PHARMACOECONOMIC EVALUATION OF
STREPTOMYCIN VERSUS ETHAMBUTOL AS
PRIMARY ANTITUBERCULAR DRUGS IN LAGOS
UNIVERSITY TEACHING HOSPITAL
Suleiman IA,Tayo F
College of Medicine, University of Lagos, Lagos, Nigeria
Available resources are very for this research is limited,
hence the need to be cost conscious. OBJECTIVES: The
purpose of the research was to know which of the two
antitubercular drugs (both of which are still actively used
in Nigeria) is more cost effective in phase I treatment 
of tuberculosis and to inﬂuence decision making.
METHOD: Cost Effectiveness Analysis was the applied
tool for these methods, and the prescribed/dispensed anti-
tubercular drugs between 1997 and 1999 were reviewed
retrospectively. Relevant information such as diagnosis,
prescribed/dispensed drugs, dosage, duration of therapy,
physician’s remarks, and cost were obtained from patient
case notes and dispensed prescriptions. These were used
in conjunction with time and motion studies and standard
cost accounting technique. The cost per deﬁned daily
dosage (DDD) was calculated, and the costs of drug/
disposables acquisition and overhead costs were included
in the analysis. The literature was reviewed for positive
and negative consequences of the considered options.
Outcome measure of effectiveness was improved in signs
and symptoms of tuberculosis/eradication of Mycobac-
terium. A decision table was used to arrive at the effec-
tiveness rating, which was compared using chi sqaure
analysis. RESULTS: The analysis showed that ethambu-
tol tab is more cost effective than streptomycin inj, which
is still widely in use. The cost/DDD of ethambutol was
N4.00/unit effectiveness while that of Streptomycin was
N65.00/unit of effectiveness. The decision did not change
when some variables were altered in favour of strepto-
mycin inj. (the less cost effective option). Increasing the
cost of ethambutol by several folds, increased the effec-
tiveness rating of streptomycin to that of ethambutol etc.,
which did not change the conclusion. CONCLUSION:
Streptomycin inj. should no longer be considered as a
primary drug in the treatment of tuberculosis, which is
still very common in Nigeria. However, the various con-
traindications/side effects of ethambutol such as optic
neuritis need to be monitored for in patient. Economic
evaluation of therapy is necessary to avoid trading-off of
more cost effective therapeutic options.
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The use of economic analysis is increasingly advocated by
funding agencies to acheive efﬁcient cost containment
strategy. OBJECTIVES: To inform the use of antibacteri-
als in chosen hospitals and to propose inclusion of eco-
nomic evaluation of drug therapy in policy formulation
and decision-making. METHODS: Cost Minimisation
Analysis; the most applicable tool for generic equivalent
drugs was used. This was compared in three health insti-
tutions. These include a tertiary, Lagos University Teach-
ing Hospital (LUTH); a secondary, General Hospital
Lagos (GHL); and a primary, Health Centre Harvey
Road, Yaba (HCHR), as well as a community pharmacy
outlet for prescriptions of GHL. Relevant information
such as diagnosis, cost of drugs, dosage, duration of
therapy among others were obtained from patient case
notes for which antibacterials are the mainstay of therapy
and dispensed prescriptions. The mean cost per deﬁned
daily dosage (DDD) of generic and branded for each
antibacterial was computed for the various hospitals.
These were compared using student ‘t’ test. The outcome
measure was erradication of bacterial in question by the
respective antibacterials. RESULTS: The use of more
expensive branded drugs is very rampant even when the
generic equivalence is available. The difference in their
cost/DDD is very signiﬁcant (P < 0.05; n = 1,576 in
LUTH, n = 1,200 in GHL, n = 900 in HCHR, n = 750
in the community pharmacy). For example, in LUTH, 
the cost/DDD of ciproﬂoxacin was N310 for branded
product and N160 for generic. Also observed were some
irrational combinations especially in the primary health
centre. CONCLUSION: A form of economic evaluation
of drug therapy is necessary for health policy and deci-
sion makers to be more informed on cost implication 
of their choices and trade-offs. Systematic appraisal of
available options needs to be well understood in view of
limited resources. Appropriate and timely intervention 
for sustainable improvement is mandatory for costs to be
greatly minimised.
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OBJECTIVES: To evaluate the impact of an inﬂuenza
vaccination campaign: decrease of attack rates of
